OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era
Jérémie Zerbit, Marion Detroit, Antoine Meyer, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2377-2377
Open Access | Times Cited: 22
Jérémie Zerbit, Marion Detroit, Antoine Meyer, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2377-2377
Open Access | Times Cited: 22
Showing 22 citing articles:
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 8
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 8
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
Saad Alhumaid, Abbas Al Mutair, Jalal Alali, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 118-118
Open Access | Times Cited: 24
Saad Alhumaid, Abbas Al Mutair, Jalal Alali, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 118-118
Open Access | Times Cited: 24
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
Dejan Jakimovski, Svetlana Eckert, Omid Mirmosayyeb, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 350-350
Open Access | Times Cited: 12
Dejan Jakimovski, Svetlana Eckert, Omid Mirmosayyeb, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 350-350
Open Access | Times Cited: 12
Xiaolu Zhu, Qian Jiang, Jin Lu, et al.
British Journal of Haematology (2023) Vol. 202, Iss. 1, pp. 31-39
Open Access | Times Cited: 12
An international multicenter study comparing COVID ‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study
Shuang Fan, Xiao‐Dong Mo, Xiaohui Zhang, et al.
Annals of Hematology (2024) Vol. 103, Iss. 4, pp. 1333-1344
Closed Access | Times Cited: 1
Shuang Fan, Xiao‐Dong Mo, Xiaohui Zhang, et al.
Annals of Hematology (2024) Vol. 103, Iss. 4, pp. 1333-1344
Closed Access | Times Cited: 1
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
Annals of Medicine (2024) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
Annals of Medicine (2024) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
Mini Kamboj, Justin C. Laracy, Shauna Usiak, et al.
Journal of Infection (2023) Vol. 87, Iss. 3, pp. 282-285
Closed Access | Times Cited: 4
Mini Kamboj, Justin C. Laracy, Shauna Usiak, et al.
Journal of Infection (2023) Vol. 87, Iss. 3, pp. 282-285
Closed Access | Times Cited: 4
Clinical features and outcomes in adults with COVID-19 during the pre-Omicron and Omicron waves
M. Martinot, Andreas Schieber, J.-C. Ongagna, et al.
Infectious Diseases Now (2023) Vol. 54, Iss. 2, pp. 104833-104833
Open Access | Times Cited: 4
M. Martinot, Andreas Schieber, J.-C. Ongagna, et al.
Infectious Diseases Now (2023) Vol. 54, Iss. 2, pp. 104833-104833
Open Access | Times Cited: 4
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 123-123
Open Access | Times Cited: 3
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 123-123
Open Access | Times Cited: 3
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
Tal Brosh‐Nissimov, Nir Maaravi, Daniel Leshin-Carmel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Tal Brosh‐Nissimov, Nir Maaravi, Daniel Leshin-Carmel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Inactivated Vaccine Dosage and Serum IgG Levels Correlate with Persistent COVID-19 Infection in Hematologic Malignancy Patients During the Omicron Surge in China
Ye Li, Ye Yang, Xuewu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Ye Li, Ye Yang, Xuewu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia
Shenmiao Yang, Rong Wei, Hongxia Shi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Shenmiao Yang, Rong Wei, Hongxia Shi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China
Ye Li, Ye Yang, Xuewu Zhang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Ye Li, Ye Yang, Xuewu Zhang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
Jassada Buaboonnam, Supattra Rungmaitree, Nuntawan Piyaphanee, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Closed Access
Jassada Buaboonnam, Supattra Rungmaitree, Nuntawan Piyaphanee, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Closed Access
Prolonged SARS‐CoV ‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
Ryosuke Kambe, Masamichi Sato, Daisuke Uehara, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Ryosuke Kambe, Masamichi Sato, Daisuke Uehara, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review
Waltraud Elisabeth Huf, Arschang Valipour
memo - Magazine of European Medical Oncology (2023) Vol. 16, Iss. 1, pp. 73-78
Open Access
Waltraud Elisabeth Huf, Arschang Valipour
memo - Magazine of European Medical Oncology (2023) Vol. 16, Iss. 1, pp. 73-78
Open Access
Real-world experience of tixagevimab–cilgavimab in High-risk, immunocompromised coronavirus disease 2019 patients
NavinaKapur Birk, NanditaChanda Kapur, Henry Castellani, et al.
Deleted Journal (2023) Vol. 1, Iss. 3, pp. 239-241
Open Access
NavinaKapur Birk, NanditaChanda Kapur, Henry Castellani, et al.
Deleted Journal (2023) Vol. 1, Iss. 3, pp. 239-241
Open Access
